Overall The UPMC Hillman Cancer Center (HCC) at University of Pittsburgh is a matrix cancer center, currently led by Robert L. Ferris, MD, PhD, who has served as Director of HCC since 2017. With funding from the National Cancer Institute and other peer- and non-peer-reviewed sources, HCC conducts impactful basic, clinical/translational, and population science research that is changing the way we detect, diagnose, and treat cancer. Through our research and community outreach efforts, we address the needs and disparities of cancer patients and those who are at risk of developing cancer in our 29-county western Pennsylvania catchment area, and through our strong efforts in educating and training new cancer researchers and clinicians, we are ensuring that those needs will continue to be met in the years to come. HCC integrates the expertise and resources of the University of Pittsburgh, a top-5 institution in NIH funding, and UPMC, one of our nation?s largest health care systems, to provide our 280 members with state-of-the-art facilities and equipment, and numerous opportunities for interaction and collaboration. Organized into 7 research programs focused on Cancer Biology, Genome Stability, Cancer Virology, Cancer Immunology and Immunotherapy, Cancer Therapeutics, Cancer Epidemiology and Prevention, and Biobehavioral Cancer Control, our members published over 4,000 articles and enrolled more than 12,700 adult and pediatric patients onto interventional clinical trials from 2014-2018. These efforts were enabled by our 10 shared resources and extensive infrastructure for supporting clinical research at central academic and community network sites. HCC is guided by an experienced Senior Leadership Team of Deputy and Associate Directors who join Dr. Ferris in overseeing our science and operations. With input from the leaders of our research programs and other key HCC members, this team sets the vision and develops the strategic plan for our future development, which includes a new HCC-wide Administrative Core for supporting team science. Over the next 5 years, HCC aims to: 1) expand upon our existing scientific strengths; 2) augment our shared resources; 3) develop and implement strategies for reducing cancer-related health problems in our catchment area population; 4) increase transdisciplinary research in topics that include tumor genomics and precision medicine, translational cancer immunotherapy, and environmental factors that impact cancers in our catchment area, and cancer and aging; 5) increase focus on education and learning at all levels of training; 6) implement precision medicine; 7) seek institutional and philanthropic funding to support faculty recruitment and retention, and the facilities and shared resources needed to advance our research initiatives; and 8) continue to engage in the dynamic planning and decision-making process that was instituted by our new Director.

Public Health Relevance

Overall The mission of the UPMC Hillman Cancer Center (HCC) is to reduce the burden of cancer in western Pennsylvania and the nation through research, patient care, education and outreach. Since its founding in 1985, HCC has been at the forefront in discovery and advancement of scientific findings that have led to new strategies for preventing, detecting, diagnosing, and treating cancer, and for addressing the health-related needs and well-being of cancer patients and survivors.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Ptak, Krzysztof
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
Schools of Medicine
United States
Zip Code
Menk, Ashley V; Scharping, Nicole E; Moreci, Rebecca S et al. (2018) Early TCR Signaling Induces Rapid Aerobic Glycolysis Enabling Distinct Acute T Cell Effector Functions. Cell Rep 22:1509-1521
Redner, Robert L; Beumer, Jan H; Kropf, Patricia et al. (2018) A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. Leuk Lymphoma 59:2595-2601
Ancevski Hunter, Katerina; Socinski, Mark A; Villaruz, Liza C (2018) PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. Mol Diagn Ther 22:1-10
Luu, Thehang; Kim, Kyu-Pyo; Blanchard, Suzette et al. (2018) Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer. Breast Cancer Res Treat 167:469-478
Pulopulos, Matias M; Vanderhasselt, Marie-Anne; De Raedt, Rudi (2018) Association between changes in heart rate variability during the anticipation of a stressful situation and the stress-induced cortisol response. Psychoneuroendocrinology 94:63-71
Shiffman, Saul; Scholl, Sarah M (2018) Three approaches to quantifying cigarette consumption: Data from nondaily smokers. Psychol Addict Behav 32:249-254
Shayan, Gulidanna; Kansy, Benjamin A; Gibson, Sandra P et al. (2018) Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. Clin Cancer Res 24:62-72
Frahm, Krystle A; Waldman, Jacob K; Luthra, Soumya et al. (2018) A comparison of the sexually dimorphic dexamethasone transcriptome in mouse cerebral cortical and hypothalamic embryonic neural stem cells. Mol Cell Endocrinol 471:42-50
Tahata, Shawn; Singh, Shivendra V; Lin, Yan et al. (2018) Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. Cancer Prev Res (Phila) 11:429-438
Moravcikova, Erika; Meyer, E Michael; Corselli, Mirko et al. (2018) Proteomic Profiling of Native Unpassaged and Culture-Expanded Mesenchymal Stromal Cells (MSC). Cytometry A 93:894-904

Showing the most recent 10 out of 1187 publications